Filgrastim and lack of support of intensive adjuvant chemotherapy for high-risk breast cancer patients

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 20, Issue 2, 1997, Pages 169-172

  Baldini, Editta ^a   Tibaldi, Carmelo ^a   Lencioni, Monica ^a   Giannessi, Piergiorgio ^a   Evangelista, Giuseppe ^b   Roncella, Manuela ^b   Spinelli, Claudio ^b   Meucci, Claudio ^b   Da Prato, Miria ^a   Conte, Pierfranco ^a,c  

^a SANTA CHIARA HOSPITAL   (Italy)

^b UNIVERSITY OF PISA   (Italy)

^c UO Oncologia Medica   (Italy)

Author keywords

Breast cancer; Filgrastrim; Intensive adjuvant chemotherapy; Ten or more metastatic axillary nodes

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; FOLINIC ACID; METHOTREXATE; PROGESTERONE RECEPTOR; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TAMOXIFEN; VINCRISTINE;

ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LYMPH NODE METASTASIS; NEUTROPENIA; ORAL DRUG ADMINISTRATION; SUBCUTANEOUS DRUG ADMINISTRATION;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; EPIRUBICIN; FEMALE; FILGRASTIM; FLUOROURACIL; HUMANS; LEUCOVORIN; LEUKOCYTE COUNT; METHOTREXATE; MIDDLE AGED; NEUTROPENIA; SURVIVAL RATE; VINCRISTINE;

EID: 17144449475     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-199704000-00014     Document Type: Article

References (7)

1. Abeloff MD, Beveridge RA, Donehower RC, et al. Sixteenweek dose intense chemotherapy in the adjuvant treatment of breast cancer. J Natl Cancer Inst 1990;82:570-4.
2. Davidson NE, Abeloff MD. Adjuvant systemic therapy in women with early-stage breast cancer at high risk for relapse. J Natl Cancer Inst 1992;84:301-5.
3. Baldini E, Lencioni M, Tibaldi C, et al. High risk breast cancer patients: an intensive adjuvant regimen administered with or without G-CSF. In: Rao RS, Deo MG, Sanghvi LD, Mittra I, eds. Proceedings of the Sixteenth International Cancer Congress New Delhi. Monduzzi, 1994:1469-72.
4. Pettengel R, Gurney H, Radford JA, et al. Granulocyte-colony stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: a randomized controlled trial. Blood 1992;80:1430-6.
5. Trillet-Lenoir V, Green JA, Manegold C, et al. Recombinant granulocyte colony-stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer 1993;29:319-24.
6. Bonadonna G, Valagussa P. Dose-response effect of adjuvant chemotherapy in breast cancer. N Engl J Med 1981;304:10-5.
7. Osborne CK, Sunderland MC, Neidhart JA, et al. Failure of GM-CSF to permit dose-escalation in an every other week dose-intensive regimen for advanced breast cancer. Ann Oncol 1994;5:43-7.